Farmas USA

Ala! Que te has vendido hasta los gayumbos! XDD

Entiendo que la mayoría de velas tienen el mismo patrón...cierta euforia inicial para luego quedarse en una mierda sesión tirando al rojo (suave) casi todas... Decepcionante día, vamos, un timo en toda regla!

pues si, una vez empiezo apretando el boton ... encadeno y no paro je,je !

calla ... que estoy mirando LABD ...

Hoy te miras LABD y mañana igual acabas comprando 3-4 farmas del tirón! Jiji ;-)

asi es , los metesacas son asi ... solo hay que ser de mente flexible.

lo de LABD me olvido, si es que no puedo estar ni al cierre, sabes lo que hago al cierre ??? contar cuentos!!!! ja,ja

Jajaja! Mientras no sean cuentos de bolsa...con el bastardo como villano...jeje

TGTX

se desinflan las pedazo carne.

Iba Caperucita por el bosque la la la y de repente aparecio el Bastardo ...

Jodo, mi mujer pide la custodia, quita, quita ...

DEPO COLL

Depomed Announces NUCYNTA® Commercialization Agreement with Collegium Pharmaceutical

https://globenewswire.com/news-release/2017/12/04/1220298/0/en/Depomed-Announces-NUCYNTA-Commercialization-Agreement-with-Collegium-Pharmaceutical.html

Depomed, Inc (NASDAQ: DEPO) today announced that it has signed a definitive Commercialization Agreement (“Agreement”) with Collegium Pharmaceutical, Inc. (“Collegium”). Under the terms of the agreement, Collegium will commercialize both NUCYNTA^® Extended Release and NUCYNTA^® Immediate Release (“NUCYNTA”).  In exchange for Collegium’s commercialization of NUCYNTA, Depomed will receive a royalty rate on all NUCYNTA revenues based on certain net sales thresholds.  As long as the agreement is in force, for the first four years, Depomed will receive a minimum royalty of $135 million per year.  After year four, the royalty mechanism remains the same but without a minimum.  The royalty rate will be adjusted post patent expiry, which Depomed believes will not occur until at least late 2025. As a result of this transaction, Depomed will eliminate its pain salesforce and cease all brand spending on NUCYNTA, thereby reducing SG&A expenses by approximately $70 million dollars on an annual basis.